We are live on ! Find out more
AVNS icon

Avanos Medical

286 hedge funds and large institutions have $548M invested in Avanos Medical in 2025 Q2 according to their latest regulatory filings, with 40 funds opening new positions, 96 increasing their positions, 65 reducing their positions, and 30 closing their positions.

New
Increased
Maintained
Reduced
Closed

48% more repeat investments, than reductions

Existing positions increased: 96 | Existing positions reduced: 65

33% more first-time investments, than exits

New positions opened: 40 | Existing positions closed: 30

3% more funds holding

Funds holding: 277286 (+9)

2.51% more ownership

Funds ownership: 94.21%96.72% (+2.5%)

12% less capital invested

Capital invested by funds: $623M → $548M (-$74.8M)

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $273K

Holders
286
Holders Change
+9
Holders Change %
+3.25%
% of All Funds
3.77%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
40
Increased
96
Reduced
65
Closed
30
Calls
Puts
$273K
Net Calls
-$273K
Net Calls Change
-$124K
Name Holding Trade Value Shares
Change
Change in
Stake
BlackRock
1
BlackRock
New York
$83.6M -$851K -67,654 -1%
Vanguard Group
2
Vanguard Group
Pennsylvania
$54.7M -$11.1M -883,401 -17%
T. Rowe Price Investment Management
3
T. Rowe Price Investment Management
Maryland
$48.9M +$3M +238,942 +6%
Dimensional Fund Advisors
4
Dimensional Fund Advisors
Texas
$31.6M -$217K -17,289 -0.7%
AC
5
Armistice Capital
New York
$24.9M +$453K +36,000 +2%
State Street
6
State Street
Massachusetts
$23.5M -$148K -11,799 -0.6%
Brown Advisory
7
Brown Advisory
Maryland
$22.1M -$1.54M -122,328 -6%
PIM
8
Paradice Investment Management
Colorado
$15.4M -$355K -28,209 -2%
ECM
9
ExodusPoint Capital Management
New York
$15.3M +$15.3M +1,217,519 +4,003%
D.E. Shaw & Co
10
D.E. Shaw & Co
New York
$14.6M +$1.29M +102,947 +9%
Geode Capital Management
11
Geode Capital Management
Massachusetts
$13.1M -$31.4K -2,497 -0.2%
Morgan Stanley
12
Morgan Stanley
New York
$10.5M +$2.17M +172,672 +25%
TCM
13
Tributary Capital Management
Nebraska
$9.92M +$925K +73,518 +10%
Charles Schwab
14
Charles Schwab
California
$8.13M +$703K +55,908 +9%
Qube Research & Technologies (QRT)
15
Qube Research & Technologies (QRT)
United Kingdom
$7.66M +$1.93M +153,547 +33%
AQR Capital Management
16
AQR Capital Management
Connecticut
$6.86M +$4.62M +367,188 +190%
CEI
17
Clark Estates Inc
New York
$6.05M
Northern Trust
18
Northern Trust
Illinois
$6M -$190K -15,107 -3%
Pacer Advisors
19
Pacer Advisors
Pennsylvania
$5.85M +$691K +54,931 +13%
JGC
20
J. Goldman & Co
New York
$5.54M +$1.68M +133,579 +42%
Prudential Financial
21
Prudential Financial
New Jersey
$4.68M +$111K +8,838 +2%
Bank of New York Mellon
22
Bank of New York Mellon
New York
$4.34M +$320K +25,472 +8%
Diamond Hill Capital Management
23
Diamond Hill Capital Management
Ohio
$4.22M +$1.88M +149,667 +77%
Invesco
24
Invesco
Georgia
$4.08M -$152K -12,073 -3%
Goldman Sachs
25
Goldman Sachs
New York
$3.6M -$1.81K -144 -0%

AVNS Hedge Fund Activity: Q2 2025 in Review

286 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Avanos Medical (AVNS) for Q2 2025, worth a combined $548M — down 12% from $623M a quarter earlier.

Buyers outnumbered sellers: 40 funds opened new AVNS positions and 30 closed out — a net gain of 10 holders — while 96 added to existing stakes and 65 trimmed.

The largest buyer was ExodusPoint Capital Management, adding an estimated $15.3M. The largest seller was Neuberger Berman Group, cutting an estimated $12.8M.

  • 286 institutional investors held Avanos Medical (AVNS) as of Q2 2025, up from 277 in Q1 2025.
  • Funds reported $548M of Avanos Medical stock for Q2 2025, down 12% quarter-over-quarter.
  • 40 funds opened new Avanos Medical positions in Q2 2025 and 30 closed out, a net change of +10 holders.
  • The largest Avanos Medical buyer in Q2 2025 was ExodusPoint Capital Management, an estimated $15.3M added.
  • The largest Avanos Medical seller in Q2 2025 was Neuberger Berman Group, an estimated $12.8M sold.

Based on aggregated 13F filings for Q2 2025.